DALLAS--(EON: Enhanced Online News)--Lantern Pharma Inc., is a clinical stage biotech company pioneering the field of precision oncology. Lantern’s proprietary approach to drug development is driven by advanced genomics and machine learning -based artificial intelligence (AI), which when combined, are advancing a new wave of precision drug therapies that significantly reduce the time to market and overall risk associated with drug development. Lantern today announced the appointment of Jeff Keyser to its board of directors.
“I look forward to working with the accomplished Lantern team in developing innovative precise treatments to improve outcomes for cancer patients who lack these options now.”
“We are very excited to welcome this distinguished biotech entrepreneur and executive to join our Board of Directors,” said Arun Asaithambi, PhD, Chief Executive Officer of Lantern Pharma. “We are at a critical inflection point for the Company and having Jeff’s expertise on the board and will be extremely valuable as we work to advance our clinical stage precision candidates to the market.”
Jeff co-founded ZS Pharma in 2008 and has over 30 years of experience in the pharmaceutical industry. Prior to joining ZS Pharma, Jeff served as the Chief Compliance Officer and Vice President of Regulatory Affairs at Encysive Pharmaceuticals. In addition, he served as Vice President of Development and Regulatory Affairs at Adams Respiratory Therapeutics and held senior management positions at Medeva Americas, Marion Merrell Dow, Marion Laboratories and Abbott Laboratories.
Jeff has experience in regulatory, medical, clinical and product development and has directed efforts to develop, prepare and secure approvals of numerous INDs and NDAs/MMAs in the United States, Canada, Australia and Europe. Jeff received his B.S. degree in pharmacy and his J.D. from Creighton University. He earned an M.P.A. from the University of Missouri at Kansas City and a Ph.D. in economics from the University of Texas at Dallas
"This is an especially exciting time for Lantern," added Jeff Keyser. "I look forward to working with the accomplished Lantern team in developing innovative precise treatments to improve outcomes for cancer patients who lack these options now."
About Lantern Pharma Inc
Lantern Pharma is a global biotech company aiming to re-invent the cancer drug development process by tailoring promising drug programs to the right cancer patients through biomarker discovery. Lantern leverages advanced genomics and machine learning based artificial intelligence (AI) to both identify and significantly reduce the cost and overall risk profile of new therapies compared to traditional drug development. Lantern currently has three clinical stage candidates in its pipeline. Tavocept is a phase 2 clinical candidate. LP-184 is being prepared for biomarker based clinical trials. Irofulven-1 has been licensed out to a later stage pharma company focused on continuing its development.